Disclosed herein are nucleic acids containing a modified internucleotide linkage, which is the 2-propyl (PrON) linkage, to increase durability and exposure of therapeutic oligonucleotides, as well as nucleotides, phosphoramidites, and other intermediate compounds useful for making the same.
C07H 19/067 - Pyrimidine radicals with ribosyl as the saccharide radical
C07F 9/06 - Phosphorus compounds without P—C bonds
C07H 21/02 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
The present disclosure relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the HMGCR receptor (expressed by the HMGCR gene), thereby decreasing expression of mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases and disorders involving the regulation of HMGCR expression and function, such as diseases and disorders that are risk factors for ASCVD (such as, dyslipidemia, such as hypercholesteremia).
Disclosed herein is a compound of formula (I): or a pharmaceutically acceptable salt thereof. Also disclosed herein is a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive. Further disclosed herein is a method for preventing or treating a disease or condition through the modulation of the glucagon receptor using a compound of formula (I), or a pharmaceutically acceptable salt thereof.
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
Provided herein are PRNP RNAi agents and compositions comprising a PRNP RNAi agent. Also provided herein are methods of using the PRNP RNAi agents or compositions comprising a PRNP RNAi agent in reducing PRNP expression and/or treating prion diseases.
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
The present disclosure provides compounds of the Formula (IX), and their pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising these compounds and their use as agonist at the human glucose-dependent insulinotropic polypeptide (GIP) in the treatment of type II diabetes mellitus and obesity.
C07D 237/04 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
A61K 31/4355 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
6.
STABLE APO-ACTIVE COMPLEX OF A G PROTEIN COUPLED RECEPTOR (GPCR) AND A G PROTEIN
Disclosed herein is a stable apo (ligand-free)-active complex of a G protein coupled receptor (GPCR) and a G protein complex, wherein the G protein complex is a cognate heterotrimeric G protein comprising an alpha subunit (Gα), a beta subunit (Gβ) and a gamma subunit (Gγ). The apo-active GPCR-G protein complex can be isolated from a cell membrane in a purified form and maintains its stability in the purified form.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
C07K 14/72 - ReceptorsCell surface antigensCell surface determinants for hormones
The present invention relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the INHBE receptor (expressed by the INHBE gene), thereby decreasing expression of mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases involving the regulation of INHBE expression and function, such as obesity or cardiometabolic disorders.
C12N 15/11 - DNA or RNA fragmentsModified forms thereof
A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
A61K 31/00 - Medicinal preparations containing organic active ingredients
A method is provided for filtering a signal received from a sensor of a medication delivery device. In some embodiments, the method includes detecting a first transition of the signal to a first logic state from a second logic state, the first transition occurring at a first time point; determining, based on the first transition of the signal, that the sensor transitioned to an engaged state at the first time point; detecting a second transition of the signal to the second logic state from the first logic state, the second transition occurring at a second time point after the first time point; and determining, based at least in part on a duration of a first time period beginning at the first time point and a duration of a second time period beginning at the second time point, whether the sensor transitioned from the engaged state to the disengaged state.
The present invention relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the ANGPTL8 receptor (expressed by the ANGPTL8 gene), thereby decreasing expression of mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases involving the regulation of ANGPTL8 expression and function, such as dyslipidemia, a cardiovascular disorder, or a cardiometabolic disorder.
The present disclosure provides a drug delivery device. The drug delivery device is taken orally by a patient, and then activates within the gastrointestinal (GI) tract of the patient. Upon activation, arms of the drug delivery device expand, and penetrating tips penetrate the GI tract walls. A driver then drives a plunger within the drug delivery device, pushing a drug through the penetrating tips and through the GI tract walls of the patient. After a period of time, part of the drug delivery device dissolves and the drug delivery device passes through the GI tract.
Applicant has amended the specification to include an Abstract. No new matter is added by way of this amendment. Applicant submits that this amendment addresses each of the informalities requiring correction listed in the Notice to File Corrected Application Papers. If the Examiner believes, for any reason, that personal communication will expedite examination of this application, the Examiner is invited to telephone the undersigned at the number provided.
Applicant has amended the specification to include an Abstract. No new matter is added by way of this amendment. Applicant submits that this amendment addresses each of the informalities requiring correction listed in the Notice to File Corrected Application Papers. If the Examiner believes, for any reason, that personal communication will expedite examination of this application, the Examiner is invited to telephone the undersigned at the number provided.
No additional fees are believed due in connection with this submission. However, in the event that additional fees are due, the Commissioner is hereby authorized by this paper to charge any additional fees associated with this submission or credit any overpayment to Deposit Account No. 05-0840, Eli Lilly and Company, associated with Customer No. 25885. Such authorization includes authorization to charge fees for extensions of time, if any, under 37 CFR 1.17 and should be treated as a constructive petition for an extension of time in this submission pursuant to 37 CFR 1.136.
A61K 31/5585 - Eicosanoids, e.g. leukotrienes having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
The present invention relates to sodium-hydrogen exchanger 3 (NHE3) inhibitor compounds of the Formula:
The present invention relates to sodium-hydrogen exchanger 3 (NHE3) inhibitor compounds of the Formula:
The present invention relates to sodium-hydrogen exchanger 3 (NHE3) inhibitor compounds of the Formula:
to pharmaceutical compositions comprising the compound and to the use of the compound for the treatment of certain diseases associated with elevated sodium and/or phosphate levels.
C07D 217/14 - Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
18.
ACTIVATION OF EGFR/HER2/3 IN CANCER AFTER TREATMENT WITH AN INHIBITOR OF FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3)
The disclosure relates to the use of a combination of an inhibitor of FGFR3 and an inhibitor of the EGFR3/HER2/3 pathway in methods of treating, preventing, or ameliorating a disease, or disorder, (or uses in the treatment, prevention, or amelioration of a disease, or disorder), in which FGFR3 plays a role. In the disclosed methods, the inhibitor of FGFR3 and the inhibitor of the EGFR/HER2/3 may be administered simultaneously, separately, or sequentially.
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
C07D 201/00 - Preparation, separation, purification, or stabilisation of unsubstituted lactams
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
19.
CONVEYOR BELT DESIGN AND PUCK NUMBER OPTIMIZATION IN MANUFACTURING NETWORK
A system for manufacturing medical devices or components includes a plurality of machines arranged with sensors for detecting fault conditions. Conveyor belts, each carrying a number of pucks to hold one or more manufactured components or intermediate products, interconnects the plurality of machines. One or more processors receives fault data generated by the sensors and inputs the fault data to a model initialized with parameters related to the plurality of machines. The model provides data indicating expected occurrences of wait states at one or more of the plurality of machines based on the fault data. Any of the one or more processors implement a first function that utilizes the model to obtain an estimate of at least one of an optimal capacity and an optimal number of pucks for each conveyor belt that is expected to minimize wait states of a target machine among the plurality of machines.
G05B 19/418 - Total factory control, i.e. centrally controlling a plurality of machines, e.g. direct or distributed numerical control [DNC], flexible manufacturing systems [FMS], integrated manufacturing systems [IMS] or computer integrated manufacturing [CIM]
G05B 17/02 - Systems involving the use of models or simulators of said systems electric
20.
GLP-1 NPA THERAPIES FOR MAINTAINING BODY WEIGHT LOSS OR REDUCED HBA1C LEVELS FOLLOWING A PRIOR GLP-1 RA TREATMENT
Disclosed herein are methods for treating a subject with T2DM, obesity, or overweight with at least one weight related comorbidity using a glucagon-like peptide-1 (GLP-1) receptor non-peptide agonist (NPA) compound selected from Compound 1, Compound 1a, Compound 2, Compound 3, pharmaceutically acceptable salts thereof, and hydrates of the compounds and pharmaceutically acceptable salts, by oral administration to maintain body weight loss or reduced HbA1c levels resulting from a prior treatment with a GLP-1 RA. Also disclosed herein are uses of a GLP-1 receptor NPA compound for the manufacture of a medicament for treating a subject with T2DM, obesity, or overweight with at least one weight related comorbidity to maintain body weight loss or reduced HbA1c levels resulting from a prior treatment with a GLP-1 RA.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
The present disclosure relates to compositions, particularly, long-acting peptide compounds having activity at the human glucose-dependent insulinotropic polypeptide receptor (GIP-R) and methods of use for treating insulin sensitivity in a patient, or a symptom or condition associated with improving insulin sensitivity.
The present invention relates to novel therapeutic compounds, known as RNAi agents, that decrease expression of the ANGPTL8 receptor (expressed by the ANGPTL8 gene), thereby decreasing expression of mRNA and protein expression. Such RNAi agents are useful in the treatment of diseases involving the regulation of ANGPTL8 expression and function, such as dyslipidemia, a cardiovascular disorder, or a cardiometabolic disorder.
Provided herein are PRNP RNAi agents and compositions comprising a PRNP RNAi agent. Also provided herein are methods of using the PRNP RNAi agents or compositions comprising a PRNP RNAi agent in reducing PRNP expression and/or treating prion diseases.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
The present invention provides novel intermediates and processes useful in the manufacture of tirzepatide, or a pharmaceutically acceptable salt thereof.
C07C 233/47 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
C07C 271/22 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
C07K 1/113 - General processes for the preparation of peptides by chemical modification of precursor peptides without change of the primary structure
C07K 14/00 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof
25.
FORMULATIONS FOR ANTI-N3pGlu AMYLOID BETA ANTIBODIES
The present disclosure is related to stable pharmaceutical formulations comprising an anti-N3pGlu amyloid beta (Aβ) antibody that specifically binds to or targets N3pGlu Aβ. In certain embodiments, the formulations contain, in addition to the antibody, a buffer, a tonicity modifier, an antioxidant, and a surfactant.
Provided herein are Activin Receptor type 2A (ACVR2A) and Activin Receptor Type 2B (ACVR2B) RNAi agents. Also provided herein are compositions comprising the ACVR2A and/or the ACVR2B RNAi agents conjugated to human transferrin receptor (TfR) binding proteins via a linker or a direct bond. Also provided herein are methods of using ACVR2A RNAi agent(s) in separate, simultaneous, or sequential combination with ACVR2B RNAi agent(s) for treating metabolic disorders, including for example, obesity, overweight, Type 2 diabetes mellitus (T2DM), and metabolic associated steatohepatitis (MASH) in a patient
Provided herein are TfR binding VHH polypeptides which bind to human and non-human primate TfR, conjugates thereof, and pharmaceutical compositions comprising these. Provided are also methods of use comprising administering TfR binding VHH polypeptides, conjugates thereof or pharmaceutical compositions thereof to deliver agents, including therapeutic agents, to treat a disease or disorder.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 31/00 - Medicinal preparations containing organic active ingredients
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A drug delivery device includes a housing, a needle, and a pressure chamber. The pressure chamber includes a shell and a port, and a flexible drug reservoir disposed in the pressure chamber and contains a drug. A pressure source is operable to provide a fluid to the pressure chamber and thereby apply fluidic pressure to an external surface of the flexible drug reservoir and compress the flexible drug reservoir. The device further includes a deformation inhibition interface including an aperture defined on one of the shell and the port. A post is coupled to the other of the shell and the port and disposed in the aperture, and the post inhibits deformation of the shell when the pressure chamber receives the fluid. Compression of the flexible drug reservoir causes the drug to flow from an internal chamber of the flexible drug reservoir to the needle.
Systems and methods are disclosed for testing the torque response of damping materials. The system and method include a rotatable arrangement of nested components with damping material disposed therebetween. In other words, a first component is rotatably arranged with a second component for rotation of the first component for a predetermined rotation angle and/or time and/or at a predetermined speed for measurement of a torque response, or resistive torque, during position movement of the first component.
G01N 11/14 - Investigating flow properties of materials, e.g. viscosity or plasticityAnalysing materials by determining flow properties by moving a body within the material by using rotary bodies, e.g. vane
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medical information services, namely providing information related to healthcare and diseases and disorders in the field of dermatology; Medical information services.
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medical information services in the field of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, psoriasis, rheumatoid arthritis, weight management, ulcerative colitis, and vascular diseases
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medical information services in the field of alopecia, Alzheimer's disease, atopic dermatitis, autoimmune diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, fibromyalgia, gastrointestinal diseases and disorders, headaches, hearing loss, kidney diseases and disorders, liver diseases and disorders, lupus, mental disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, osteoarthritis, pain, Parkinson's disease, psoriasis, rheumatoid arthritis, weight management, ulcerative colitis, and vascular diseases.
The present invention provides a compound of Formula I:
The present invention provides a compound of Formula I:
wherein R is H or
The present invention provides a compound of Formula I:
wherein R is H or
R1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3,
The present invention provides a compound of Formula I:
wherein R is H or
R1 is H, halogen, C1-C3 alkyl, C3-C6 cycloalkyl, C1-C3 alkoxy, C2-C3 alkenyl, OCF3,
R2 is H, halogen, C1-C3 alkyl, C1-C3 alkoxy, or C2-C4 alkenyl;
R3 is NH2, or CH2NH2; and
X is O, OCH2, OCH2CH2, OCH(CH3), CH2O, SCH2, CH2S, CH2, NHCH2, CH2NH, N(CH3)CH2, CH2CH2, C≡C, or a bond, wherein X is connected to phenyl ring A at the ortho or the meta position, or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is useful for treating autoimmune and inflammatory diseases, such as atopic dermatitis and rheumatoid arthritis.
The present disclosure relates to methods for preparing enantiomeric compounds (such as tricyclic heteroaryl carboxamide compounds) useful at least for treating certain immune-mediated diseases. Intermediates disclosed herein include, for example a compound of formula: The disclosure also relates to a solid form of a compound so prepared.
A61K 31/435 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
4-PHENYL-1H-PYRAZOLO[3,4-B]PYRIDINE-5-CARBOXAMIDE DERIVATIVES AS AMYLIN AND/OR CALCITONIN RECEPTOR AGONISTS FOR THE TREATMENT OF TYPE 2 DIABETES, OBESITY OR OVERWEIGHT
Disclosed herein is a 4-phenyl-lH-pyrazolo[3,4-b]pyridine-5- carboxamide derivative of formula (I) as amylin and/or calcitonin receptor agonists for the treatment of type 2 diabetes, obesity or overweight.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
62.
MEDICATION DELIVERY DEVICE WITH DOSE DETECTION SYSTEM
The present disclosure relates to a medication delivery device having a dose detection system and an associated control system configured to determine an amount of medication delivered from the medication delivery device based on the sensing of relative rotation within the medication delivery device. The relative rotation may occur between a dose setting member and an actuator and/or housing of the medication delivery device. The rotation sensing may involve sliding contact sensing. A latch circuit may be coupled between the rotational sensor and the controller. The dose detection system may be a modular or integral component of the medication delivery device.
A medication delivery device includes a disposable portion and a reusable portion. The disposable portion includes a therapeutic agent delivery assembly, and the therapeutic agent delivery assembly includes a needle. The therapeutic agent delivery assembly is translatable from a stowed configuration to a deployed configuration. The reusable portion includes a first rack and pinion mechanism and a second rack and pinion mechanism. The first rack and pinion mechanism is actuatable to translate the therapeutic agent delivery assembly from the stowed configuration to the deployed configuration. The second rack and pinion mechanism is actuatable to translate a plunger and thereby cause the therapeutic agent delivery assembly to deliver a therapeutic agent from the needle.
Medication delivery devices having a dosage button which may be translated in a distal direction to set a predetermined dosage of a medication or other therapeutic agent and translated in a proximal direction to deliver said medication. Some dosage assemblies including the dosage button may additionally rotate relative to a body of the medication delivery device.
Medication delivery devices having a dosage button which may be translated in a distal direction to set a predetermined dosage of a medication or other therapeutic agent and translated in a proximal direction to deliver said medication. Some dosage assemblies including the dosage button may additionally rotate relative to a body of the medication delivery device.
a bb are as described herein, pharmaceutically acceptable salts thereof, and methods of using these compounds and pharmaceutically acceptable salts thereof for treating patients for cardiovascular, pulmonary and/or renal conditions, diseases and/or disorders.
A61K 31/36 - Compounds containing methylenedioxyphenyl groups, e.g. sesamin
A61K 31/423 - Oxazoles condensed with carbocyclic rings
A61K 31/428 - Thiazoles condensed with carbocyclic rings
C07D 277/60 - Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
C07D 317/62 - Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
C07D 317/66 - Nitrogen atoms not forming part of a nitro radical
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61P 9/02 - Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
The present invention relates to doses and dosing regimens of an NRG4 compound in the treatment of cardiovascular disease (CVD) related conditions, including heart failure (HF).
The present disclosure provides PTK-7 antibody drug conjugates and pharmaceutical compositions thereof, and methods of using for the treatment of cancer.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
The present invention relates to antibodies that bind to human CD137 and display agonist activity, and may be useful for treating solid and hematological tumors alone and in combination with anti-human PD-1 antibodies, chemotherapy, and ionizing radiation.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Compositions comprising lipid nano delivery particles for the targeted transport of nucleic acids as well as methods of manufacturing and using lipid nano delivery particles in the targeted transport of nucleic acids once administered to patients.
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
86.
PROTEIN TYROSINE KINASE 7 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
The present disclosure provides PTK-7 antibody drug conjugates and pharmaceutical compositions thereof, and methods of using for the treatment of cancer.
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
C07D 491/22 - Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups , , or in which the condensed system contains four or more hetero rings
A61K 47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
C12N 15/79 - Vectors or expression systems specially adapted for eukaryotic hosts
The techniques provide for non-invasive gastrointestinal sampling. In some embodiments, a device includes a capsule housing bounding a cavity, a sampling aperture formed in the capsule housing and providing fluid communication between the cavity and an exterior of the capsule housing, a luminescent substrate layer positioned within cavity, the luminescent substrate being configured to emit a luminescent light upon exposure to a sample fluid containing a luminescing trigger, and at least one additional substrate layer positioned within the cavity between the sampling aperture and the luminescent substrate, each of the at least one additional substrate layers being configured to chemically interact with the sample fluid. The device also includes a photodetector positioned within the cavity, the photodetector configured to detect the luminescent light, and a biodegradable coating closing the sampling aperture such that degradation of the biodegradable coating exposes the sampling aperture to permit fluid flow into the cavity.
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
A61B 5/1459 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using optical sensors, e.g. spectral photometrical oximeters invasive, e.g. introduced into the body by a catheter
91.
BAFFR X CD3 BISPECIFIC ANTIBODIES AND METHODS OF USE
The present invention relates to antibodies that specifically bind human BAFFR, to bispecific antibodies that specifically bind to both human BAFFR and human CD3, compositions comprising such antibodies, and methods of using the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Disclosed herein is a tablet composition comprising 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt thereof, and a pH modifier. In one embodiment, a tablet composition comprises a spray dried dispersion (SDD) of 3-[(1S,2S)-1-[5-[(4S)-2,2-dimethyloxan-4-yl]-2-[(4S)-2-(4-fluoro-3,5-dimethylphenyl)-3-[3-(4-fluoro-1-methylindazol-5-yl)-2-oxoimidazol-1-yl]-4-methyl-6,7-dihydro-4H-pyrazolo[4,3-c]pyridine-5-carbonyl]indol-1-yl]-2-methylcyclopropyl]-4H-1,2,4-oxadiazol-5-one, or a pharmaceutically acceptable salt thereof, wherein the SDD also comprises a polymer to maintain an amorphous state.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
Disclosed herein is a compound of formula (I): or a pharmaceutically acceptable salt thereof. Also disclosed herein is a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive. Further disclosed herein is a method for preventing or treating a disease or condition through the modulation of the glucagon receptor using a compound of formula (I), or a pharmaceutically acceptable salt thereof.
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
94.
GLUCAGON RECEPTOR AGONISTS AND THEIR USE AS THERAPIES
Disclosed herein is a compound of formula (I): (I), or a pharmaceutically acceptable salt thereof. Also disclosed herein is a pharmaceutical composition comprising a compound of formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable additive. Further disclosed herein is a method for preventing or treating a disease or condition through the modulation of the glucagon receptor using a compound of formula (I), or a pharmaceutically acceptable salt thereof.
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
95.
ENDOCRINE THERAPY AND ABEMACICLIB COMBINATION FOR THE ADJUVANT TREATMENT OF NODE-POSITIVE, EARLY STAGE, HORMONE RECEPTOR-POSITIVE, HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE BREAST CANCER
The present invention discloses an adjuvant treatment of node-positive, carly stage, hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2—) breast cancer comprising administering an effective amount of an endocrine therapy in combination with an effective amount of abemaciclib or a pharmaceutically acceptable salt thereof.
A61K 31/5685 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone having an oxo group in position 17, e.g. androsterone
A61P 35/04 - Antineoplastic agents specific for metastasis
96.
COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES
The invention provides compositions and methods for inducing satiety or treating a metabolic condition. The compositions include polypeptides, which can be used to provide treatment for obesity and metabolism related disorders.
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
A61K 9/02 - SuppositoriesBougiesBases for suppositories or bougies
Incretin analogs are provided that have activity at each of the GIP, GLP-1 and glucagon receptors. The incretin analogs have structural features resulting in balanced activity and extended duration of action at each of these receptors. Methods also are provided for treating diseases such as diabetes mellitus, dyslipidemia, fatty liver disease, metabolic syndrome, non-alcoholic steatohepatitis and obesity.
09 - Scientific and electric apparatus and instruments
Goods & Services
Software application for verifying the authenticity of pharmaceutical products; software for scanning and decoding barcodes on medicine packaging; software for querying manufacturing databases to confirm product origin and authenticity; software that provides verification results indicating whether a scanned product is authentic, counterfeit, unsupported, or not recognized; software for use in pharmaceutical supply chain integrity and anti-counterfeiting measures.
09 - Scientific and electric apparatus and instruments
Goods & Services
(1) Software application for verifying the authenticity of pharmaceutical products; software for scanning and decoding barcodes on medicine packaging; software for querying manufacturing databases to confirm product origin and authenticity; software that provides verification results indicating whether a scanned product is authentic, counterfeit, unsupported, or not recognized; software for use in pharmaceutical supply chain integrity and anti-counterfeiting measures.
